Cardiol sees phase 2 Archer study results published

Executive Summary

• Cardiol Therapeutics announced the publication of Phase 2 Archer study results in the peer-reviewed journal ESC Heart Failure.
• The study evaluated CardiolRx in 109 patients with acute myocarditis, demonstrating significant reduction in left ventricular mass and left atrial remodelling compared to placebo.
• The results support the biological rationale for the ongoing pivotal Phase 3 Maveric trial in recurrent pericarditis, citing the shared spectrum of inflammatory myopericardial syndrome.

Key Details

• Publication Venue: ESC Heart Failure, a journal of the European Society of Cardiology.
• Study Design: Randomized, double-blind, placebo-controlled trial.
• Patient Population: 109 patients with acute myocarditis.
• Primary Findings:
  • Significant reduction in left ventricular mass versus placebo.
  • Decrease in left atrial remodelling.
  • Favourable trends across multiple markers of myocardial inflammation.
  • CardiolRx was shown to be safe and well-tolerated.
• Clinical Significance: Reduction in left ventricular mass is considered consistent with decreased myocardial edema and inflammatory burden, which is linked to improved clinical outcomes.
• Strategic Relevance: Biological signals from Archer are directly relevant to the ongoing Phase 3 Maveric trial for recurrent pericarditis, as both conditions fall under the umbrella of inflammatory myopericardial syndrome.
• Pipeline Context:
  • Maveric Program: Pivotal Phase 3 trial (NCT06708299) for recurrent pericarditis; previously completed Phase 2 pilot (NCT05494788). CardiolRx has orphan drug designation for pericarditis from the FDA.
  • Archer Program: Completed Phase 2 study (NCT0518240) for acute myocarditis.
  • CRD-38: Novel subcutaneous formulation in development for inflammatory heart disease, including heart failure.

Notable Quotes

• "This publication marks an important moment in the broader dissemination of CardiolRx's therapeutic potential... Archer provides additional compelling clinical evidence that CardiolRx impacts the underlying biology of inflammatory heart disease and reduces inflammation-driven structural damage in the heart, increasing our confidence in Maveric, which is focused on delivering meaningful outcomes for patients with recurrent pericarditis." — David Elsley, President and CEO